Insidious iron burden in pediatric patients with acute lymphoblastic leukemia

Area of Science:

• Pediatric Hematology Oncology
• Transfusion Medicine
• Iron Metabolism

Background:

• Hematologic disorders, particularly acute lymphoblastic leukemia (ALL), often necessitate frequent blood transfusions.
• Significant iron burden can accumulate after a limited number of transfusions, posing a risk to patients.
• Quantifying transfusion-related iron load in pediatric ALL patients is crucial for understanding long-term health implications.

Purpose of the Study:

• To quantify the volume of transfused blood and resultant iron load in a large cohort of pediatric patients with ALL.
• To evaluate risk factors, such as ALL risk category, that influence transfusion volume.
• To assess the correlation between patient characteristics and blood transfusion volumes.

Main Methods:

• A retrospective study was conducted on 107 pediatric patients who completed ALL therapy.
• Data collected included age, weight, hemoglobin at presentation, ALL risk category, and blood transfusion volumes.
• Statistical analysis was performed to identify associations between variables.

Main Results:

• Patients received an average of 115 ml/kg of blood, equating to 77 mg/kg of iron.
• A significant association was found between packed red blood cell volume and ALL risk category.
• High-risk ALL patients received substantially more iron (196 ml/kg) compared to standard-risk (90 ml/kg) or T-cell ALL (114 ml/kg) patients.

Conclusions:

• Pediatric patients with ALL accumulate a substantial iron load during therapy, with higher-risk patients bearing the greatest burden.
• Iron overload shares toxicity with chemotherapy and is treatable, suggesting the need for screening.
• Screening for iron burden and related morbidities should be considered in long-term ALL follow-up, especially for high-risk cases.